Genome-wide association studies associated with Alzheimer's disease (AD) have 40 implicated pathways related to both lipid homeostasis and innate immunity in the 41 pathophysiology of AD. However, the exact cellular and chemical mediators of 42 neuroinflammation in AD remain poorly understood. The oxysterol 25-hydroxycholesterol 43 (25-HC) is an important immunomodulator produced by peripheral macrophages with 44 wide-ranging effects on cell signaling and innate immunity. Genetic variants of the 45 enzyme responsible for 25-HC production, cholesterol 25-hydroxylase (CH25H), have 46 been found to be associated with AD. In the present study, we found that the CH25H 47 microglial secreted inflammatory mediator in brain, promoting IL1b-mediated 61 neuroinflammation in an apoE isoform-dependent manner (E4>>E2/E3) and thus may be 62 an important mediator of neuroinflammation in AD. 63 64
expression is upregulated in human AD brain tissue and in transgenic mouse brain tissue 48 bearing amyloid-b (Ab) plaques or tau pathology. Treatment with the toll-like receptor 4 49 (TLR4) agonist lipopolysaccharide (LPS) markedly upregulates CH25H expression in the 50 mouse brain in vivo. LPS also stimulates CH25H expression and 25-HC secretion in 51 cultured mouse primary microglia. We also found that LPS-induced microglial production 52 of the pro-inflammatory cytokine IL1b is markedly potentiated by 25-HC and attenuated 53 by genetic deletion of CH25H. Microglia expressing apolipoprotein E4 (apoE4), a genetic 54 risk factor for AD, produce greater amounts of 25-HC than apoE3-expressing microglia 55 following treatment with LPS. Remarkably, treatment of microglia with 25-HC results in a 56 much greater level of IL1b secretion in LPS-activated apoE4-expressing microglia than in 57 apoE2-or apoE3-expressing microglia. Blocking potassium efflux or inhibiting caspase-1 58 prevents 25-HC-potentiated IL1b release in apoE4-expressing microglia, indicating the 59 involvement of caspase-1/NLRP3 inflammasome activity. 25-HC may function as a 60 Introduction 65 66
Neuroinflammation is a prominent feature of the neuropathology of Alzheimer's 67 disease (AD), in addition to β-amyloid (Aβ) plaques and tau-containing neurofibrillary 68 tangles (NFT) (1) . Emerging evidence indicates that neuroinflammation, mediated by 69 activated glial cells, plays a fundamental role in the pathogenesis and neurodegeneration 70 of AD (1) . Brain inflammation either triggered by or proceeding AD pathology sustains 71 and likely contributes to the progressive neurodegeneration that characterizes AD (2). 72
Defining the molecular and cellular mechanisms underlying neuroinflammation as well as 73 the chemical mediators of the inflammatory cascade are critical for understanding how 74 neuroinflammation contributes to AD pathogenesis. 75
In AD, neuroinflammation increases with disease progression and is primarily 76 driven by glial cells, especially microglia. This pathophysiological inflammatory cascade 77 is associated with increased production of pro-inflammatory cytokines and other key 78 inflammatory mediators (3, 4), including interleukin-1β (IL-1β), a very potent pro-79 inflammatory cytokine (5-8). Higher concentrations of IL-1b have been reported in 80 cerebrospinal fluid and brain tissue of AD patients (9-11) and in microglia surrounding Ab 81 plaques (12). Sustained elevations of IL-1b have been postulated to play a key role in AD 82 pathogenesis (6, 12-14). Active IL-1β (17kD) is produced from an inactive 31 kDa pro-IL-83 1β by the inflammasome, a multicomponent protein complex consisting of NLRP3 84 (nucleotide-binding domain and leucine-rich repeat-containing protein 3), ASC 85 (apoptosis-associated speck-like protein containing a CARD) and caspase-1(15). The 86 elevations of IL-1β reported in AD brain strongly suggests activation of the inflammasome 87 (16). Supporting this, aggregated Ab has been shown to activate the inflammasome via 88 a CD36/TLR4/6-dependent mechanism (17). NLRP3 deficiency reduces amyloid 89 deposition and rescues memory deficits in the APP/PS1 model of AD (18). Understanding 90 the cellular mechanisms responsible for IL-1b production by microglia may facilitate the 91 development of an effective AD therapeutic that reduces IL-1b-mediated immune 92 signaling and associated neuroinflammation. 93
The apolipoprotein E4 (APOE4) allele is the most common and important genetic 94 risk factor for late onset AD (19-21). In the periphery, apoE regulates lipid metabolism 95 (22, 23). In brain, apoE functions as an important regulator of brain amyloid (amyloid b-96 peptide or Ab) deposition and clearance (apoE2>E3>E4), which most likely accounts for 97 one of the known mechanisms as to how APOE4 increase AD risk (24). Recently, several 98 studies have shown that APOE4 is associated with increased innate immune reactivity 99 and enhanced cytokine secretion in primary microglia and peripheral macrophages in 100 various animal models as well as human subjects (25-36). We have also reported a higher 101 innate immune reactivity of apoE4-expressing microglia following LPS treatment and 102 found that APOE4/4 genotype greatly influences tau-dependent neuroinflammation in a 103 tau transgenic mouse model of neurodegeneration (37). Together, these data suggest 104 that apoE4 may exert a "toxic" gain of function to promote microglia-mediated 105 neuroinflammation and neurodegeneration in AD. 106 25-hydroxycholesterol (25-HC) is a potent oxysterol regulator of cholesterol 107 biosynthesis (38-40). It is converted from cholesterol by the oxidoreductase cholesterol 108 25-hydroxylase (CH25H) (41, 42), an enzyme highly expressed and induced primarily in 109 peripheral macrophages and dendritic cells in response to inflammatory stimuli like LPS 110 and interferon (43, 44) . Although CH25H deficiency does not cause defects in cholesterol 111 homeostasis (44, 45), 25-HC appears to serve multiple functions to regulate both innate 112 and adaptive immunity. It acts as either an anti-or pro-inflammatory regulator involved in 113 protection from viral infection, macrophage foam cell formation, immunoglobin IgA 114 production and cytokine production (44). To date, the function of CH25H and 25-HC in 115 the central nervous system has not been well characterized. The association of CH25H 116
with AD was first reported in a hippocampal microarray study of AD brain tissue (46) and 117 further supported by an AlzGene meta-analysis for a sporadic AD population (47) and 118 other AD patient-based independent systematic analyses (48-50). Upregulation of 119 CH25H mRNA in affected brain regions in AD patients versus controls was first reported 120 in a hippocampal microarray. Upregulation of CH25H expression has also been detected 121 in brain tissue of AD transgenic mice (51-53). It remains unclear exactly how CH25H and 122 its oxysterol product 25-HC are involved in AD. 123
In the present study, we investigated whether 25-HC regulates the innate immune 124 response of microglia and whether the APOE4 allele relative to the other common APOE 125 alleles impacts the effects of 25-HC on microglial activation. Our results demonstrate that 126 CH25H is upregulated in AD brain tissue and AD transgenic mouse brain. We further 127
show that 25-HC is produced by activated primary microglia and augments IL-1b 128 production stimulated by the TLR4 agonist LPS. Importantly microglia expressing apoE4 129 produce much greater amounts of 25-HC and IL-1b in response to LPS treatment 130 compared to apoE2-or apoE3-expressing microglia. Remarkably, 25-HC also markedly 131 potentiates LPS-mediated IL-1b secretion by apoE4-expressing microglia. Inhibition of 132 inflammasome activity markedly reduces augmentation of microglial IL-1b secretion by 133 25-HC. Our results suggest that 25-HC may function as an inflammatory mediator of the 134 IL-1b-dependent inflammatory cascade in microglia and thus, may contribute to apoE4-135 dependent neuroinflammation and neurodegeneration in AD. 136
137
Results: 138 139
CH25H is upregulated in human AD brain and AD-related transgenic mouse brain. 140
We first examined the expression of CH25H in postmortem human AD brain tissue. Using 141 quantitative PCR, we observed that the level of CH25H mRNA was significantly 142 upregulated in frontal cortical tissue of AD brain (n=14) compared to age-matched (non-143 AD) controls (n=9, p<0.05) ( Fig.1a , all subjects were age>80 and both genders included). 144
The protein level of CH25H was also increased in AD brain tissue as detected by Western 145
Blot using a CH25H antibody (Fig. 1b ). The increased levels of CH25H mRNA and protein 146 were also observed in the frontal cortex of 4-mo old APPPS1-21 mice bearing amyloid 147 plaques (54) ( Fig.1c, d, e ). We further examined the expression of CH25H in PS19 mice 148 expressing the human P301S tau mutation at 9-mo of age bearing massive tau pathology, 149 inflammation and neurodegeneration in brain (55). Compared to their age-matched non-150 tg littermates, we detected an increase of CH25H mRNA in the brain of PS19 tg mice 151 ( Fig. 1f ). Moreover, when we measured CH25H mRNA levels in the frontal cortex of 152 P301S tau transgenic mice that are homozygous for human APOE2 (TE2), APOE3 (TE3), 153 APOE4 (TE4) or with no expression of apoe (TEKO) using nanostring analysis, we found 154 that TE4 mice, an aggressive mouse model showing the strongest brain 155 neurodegeneration and neuroinflammation (37), express significantly higher levels of 156 CH25H mRNA than TEKO mice, and also showed higher levels of CH25H expression 157 than TE2 or TE3 mice although these comparisons did not reach statistical significance 158 ( Fig. 1g ). Together these data suggest that CH25H expression is upregulated in human 159 AD brain and mouse brain when there is prominent amyloid or tau pathology and 160 neuroinflammation. Given that we measured CH25H mRNA and protein in brain tissue 161 and not in individual microglia, these data are all the more noteworthy. 162 LPS stimulates 25-HC production and CH25H expression in primary microglia. In 163 macrophages, the TLR4 agonist lipopolysaccharide (LPS) stimulates expression of 164 CH25H and production of 25-HC (43). In the central nervous system, CH25H is mainly 165 expressed in microglia, the counterpart of peripheral macrophages, with very limited 166 expression, if any, in other brain cell types, based on the Stanford transcriptome database 167 generated by Barres group (http://www.brainrnaseq.org) (Supplemental Fig.1a ). To 168 explore a potential role for CH25H and its oxysterol product 25-HC in microglia-mediated 169 innate immunity, we first measured 25-HC production by LC/MS in cultured microglia 170 isolated from brain tissue of neonatal wild type mice in response to stimulation by LPS. A 171 time-and dose-dependent increase of 25-HC production was observed in the cell lysate 172 and medium of LPS-treated microglia compared to untreated microglia ( Fig. 2a, b ). As 173 measured by qPCR, LPS stimulated the expression of the pro-inflammatory cytokines IL-174 1b and TNFa as well as inflammasome genes such as NLRP3. It also potently 175 upregulated CH25H mRNA in microglia (≥50 fold) ( Fig. 2c ). The increase in CH25H 176 expression induced by LPS was further confirmed by Western blot using a CH25H 177 specific antibody ( Fig. 2c , insert). We next evaluated the effects of LPS on CH25H 178 expression in the mouse in vivo. Wild type mice were treated with LPS (8.2mg/kg via i.p.) 179 for 24 hrs, a marked increase in CH25H mRNA was detected in the hippocampus and 180 cerebral cortex of LPS-treated mice compared to vehicle-treated mice (Fig. 2d ). In 181 contrast, the expression of CYP27a1 or CYP7b1 (two other enzymes involved in the 182 cholesterol:oxysterol metabolic pathway) were not influenced by LPS treatment (Fig. 2d) , 183
suggesting that the induction of CH25H by LPS was highly specific. These results 184 demonstrate that the production of 25-HC and the expression of CH25H are highly 185 responsive to TLR4 stimulation in cultured primary microglia as well as in mouse brain in 186 vivo. 187
Depletion of 25-HC selectively attenuates LPS-induced IL-1β expression in primary 188
microglia. To examine whether 25-HC is involved in the inflammatory response of 189 microglia, we eliminated 25-HC production using microglia prepared from CH25H 190 knockout (KO) mice (supplementary Fig. 1b ). When WT or CH25H KO microglia were 191 treated with LPS, we observed a significant reduction in the level of IL-1β secreted into 192 the medium of CH25H KO microglia compared to WT microglia (Fig. 3a ). The levels of 193 IL-1a, a cytokine often co-released with IL-1b, were also reduced ( Fig. 3b ). In contrast, 194 the production of TNFα ( Fig. 3c ) or IL-6 (not shown) were similar in both WT and CH25H 195 KO cells treated with LPS. The addition of 25-HC to CH25H KO microglia fully rescued 196 the attenuated IL-1b/a production observed in CH25H KO microglia to a comparable level 197 as WT microglia (Fig. 3d ). These data suggest that 25-HC contributes to the LPS-198 triggered IL-1β production by microglia. To directly evaluate the effect of 25-HC on IL-199 1β/α production, we treated WT microglia with 25-HC alone or in combination with LPS. 200
Compared to LPS treatment alone, the addition of 25-HC in the presence of LPS resulted 201 in a marked dose-dependent increase of microglial IL-1β and IL-1α secretion while 25-202 HC treatment alone had no effect ( Fig. 3e ). 203
204
Mature IL-1β (17kDa) is produced from its 31 kDa pro-IL-1β by the inflammasome 205 complex and rapidly secreted into medium. We next examined the effects of 25-HC on 206 the level of pro-IL-1β protein remaining in cells and mature IL-1β protein released into the 207 medium by Western blotting. LPS treatment markedly increased the cellular level of pro-208 IL-1b as well as the inflammasome proteins NLRP3 and ASC1, resulting in a limited 209 amount of 17kDa IL-1b produced and secreted into the medium. However, the addition 210 of 25-HC markedly and dose-dependently stimulated the release of active 17kDa IL-1b 211 into the medium (Fig. 3f ). The intracellular protein levels of unprocessed pro-IL-1β, 212 NLRP3 or ASC were not influenced by the presence of 25-HC ( Fig. 3f ). Therefore, 25-HC 213 may regulate IL-1β production at a posttranslational level. Together, these results suggest 214 that 25-HC modulates LPS-activated inflammatory responses by selectively promoting 215 mature IL-1β production. 216 217 APOE4-expressing microglia show exaggerated IL-1b production in response to 218 LPS and 25-HC treatment. Previous studies have shown that APOE isoforms 219 differentially influence the innate immune response of microglia (26, 27). We therefore 220 examined the effects of the common APOE isoforms on both LPS and 25-HC-enhanced 221 production of IL-1β in microglia. Microglia were prepared from neonatal mice expressing 222 human APOE2 (E2), APOE3 (E3), or APOE4 (E4) at the mouse APOE locus (56-58). 223
Consistent with previous reports, E4-expressing microglia produced higher levels of IL-224 1β than E2-expressing cells or APOE deficient cells (EKO) after 6 h ( Fig. 4a ) or 24 h ( Fig.  225 4b) following LPS treatment alone. As expected, 25-HC dose-dependently increased IL-226 1β production at 6 h ( Fig. 4a ) and at 24 h ( Fig. 4b) . Strikingly, co-incubation with 25-HC 227 resulted in a marked potentiation of IL-1β production in E4-expressing microglia 228 compared to E2-expressing or EKO microglia at each concentration of 25-HC tested ( Fig.  229 4a and 4b), resulting in significantly higher levels of IL-1β production from E4 microglia 230 than that from E2 or EKO microglia ( Fig. 4a and 4b ). Although LPS induced greater IL-6 231 production in E4-expressing microglia, 25-HC treatment did not influence the production 232 of IL-6 ( Fig. 4c ). We further compared the IL-1b-inducing activity of 25-HC between E4 233 and E3 microglia. A higher amount of secreted (extracellular) IL-1β was observed in E4 234 microglia than in E3 microglia treated with both LPS and 25-HC ( Fig. 4d ). Consistently 235 we detected more mature IL-1β protein (17kd) in the medium of E4 microglia than in the 236 medium of E3 microglia, while the levels of intracellular pro-IL-1β did not increase in cells 237 treated with 25-HC ( Fig. 4e ). Together, these data demonstrate that apoE isoforms 238 differentially influence the ability of 25-HC to augment the secretion of IL-1β production 239 in LPS-activated microglia and the presence of APOE4 markedly augments the effects of 240 25-HC in promoting IL-1β production, shifting the dose-response for 25-HC substantially 241 to the left. Lastly, the production of 25-HC by E2 or E4-expressing microglia was 242 measured. We also found that E4 microglia produced greater amount of 25-HC measured 243 in both cells and medium than E2 microglia when treated with LPS ( Fig. 4f) . 244 245
Augmentation of LPS-induced IL-1β induction by 25-HC is enantioselective.
To 246 examine the specificity of 25-HC, we first tested the effects of both the 25-HC precursor 247 cholesterol and another cholesterol metabolite 7a-HC on IL-1b production. Comparing to 248 the promoting effects of 25-HC on IL-1b/a production, coincubation of cholesterol or 7a-249 HC with LPS at a similar concentration as 25-HC did not promote LPS-induced IL-1b/a 250 production in microglia ( Fig. 5a , b, c). We further evaluated the IL-1b-inducing activity of 251 ent-25-HC, the inactive enantiomer of 25-HC (59), and found that ent-25HC exhibited only 252 very weak IL-1b-inducing activity and was at least an order of magnitude less potent than 253 25-HC (Fig. 5d ). These results demonstrate that the IL-1b induction by 25-HC is 254 enantioselective and thus likely mediated via a specific protein target(s). The number of ASC speck-containing cells significantly increased following treatment with 264 LPS and 25-HC compared to LPS alone ( Fig. 6a ). 25-HC treatment alone, however, did 265 not induce ASC speck formation ( Fig. 6a, b ). We further found that the induction of ASC 266 speck by LPS and 25-HC is dependent on TLR4, because no ASC speck formation was 267 detected in TLR4 KO microglia treated with LPS and 25-HC ( Fig. 6c, d ). The induction of 268 IL-1β by LPS and 25-HC was also markedly reduced or eliminated in TLR4 KO microglia 269 ( Fig. 6c, d) . These data suggest that 25-HC augments IL-1β secretion via activation of 270 the inflammasome in a TLR4-dependent manner. Activation of NLRP3 inflammasome 271 triggers oligomerization of caspase-1 that cleaves pro-IL-1b to biologically active IL-1b. 272
To examine if the induction of IL-1b by 25-HC is caspase-1-dependent, primary microglia 273 were treated with LPS and 25-HC in the presence of VX765, a prodrug of VRT-043198 274 that selectively inhibits the caspase-1 subfamily of cysteine proteases (61). Treatment 275 with VX765 completely inhibited the effect of 25-HC on IL-1b production ( Fig. 6e) , 276
suggesting that 25-HC induces IL-1b production by activating the inflammasome and 277 caspase-1. Potassium efflux is one of the common mediators of NLRP3 inflammasome 278 activation in response to diverse stimuli (15). When potassium efflux was blocked by a 279 high concentration of extracellular KCl, we found that the induction of IL-1b by LPS and 280 25-HC was effectively prevented by 50mM KCl (Fig. 6f ). This result confirms that 281 activation of the inflammasome by LPS is augmented by 25-HC and further suggests that have been widely documented (see below), it has also been reported to have 300 proinflammatory effects and may contribute to the tissue damage in mice observed 301 following influenza infection by acting as an amplifier of inflammation by macrophages via 302 an AP-1-mediated mechanism (64). CH25H deficient mice have also been reported to 303
show decreased inflammatory-mediated pathology and death following influenza infection 304 Swiss, Mediterranean), a significant association of rs13500 'T' allele and haplotypes in 325 CH25H promoter were found to be significantly associated with the risk of developing AD 326 and with different rates of Ab/amyloid deposition (47). Although the association of this 327 rs13500 promoter polymorphism was not found in two sequent studies (68, 69), a recently 328 study carried out in a Turkish cohort of AD subjects and controls also revealed a strong 329 association of CH25H rs13500 and AD, and an even stronger risk factor in the presence 330 of APOE4 (70). More recently, several genome-wide expression studies carried out in 331 models of accelerated aging, AD pathology and neuroinflammation have all identified 332 CH25H as being significantly upregulated in brain (51-53). Here we also show that 333 CH25H is upregulated in AD brain tissue compared to age-matched controls as well as 334 in two mouse models of AD pathology; APPPS1 transgenic mice, tau transgenic mice 335 and a recently described APOE4xP301S (TE4) tau transgenic mouse model of 336 accelerated tau pathology and neurodegeneration (37). These findings suggest that 25-337 HC may be involved in AD pathogenesis, especially given its reported proinflammatory 338
properties and our data on its marked potentiation of cytokine expression and secretion 339 from microglia stimulated by the TRL4 agonist, LPS. 340 341 CH25H, 25-HC and APOE genotype. Given the important role of APOE4 as a genetic 342 risk factor for AD and its reported role in regulating innate immunity in brain (71), we 343 examined whether CH25H expression and 25-HC production in microglia were impacted 344 by APOE genotype. First, we found that apoE4-expressing microglia produced 345 significantly more 25-HC in response to LPS treatment than apoE2-expressing microglia. 346
We also found that apoE4-expressing microglia produced more IL-1b and IL-6 in 347 response to LPS treatment as has been previously reported (27). To our surprise, co- In vitro, apoE4-expressing microglia exhibit higher "innate immune reactivity" following 358 LPS treatment measured by both cytokine and NO production (27). Moreover, APOE 359 genotype alters glial activation in response to LPS treatment (72). Together, with our in 360 vivo data in several AD mouse models demonstrating higher brain levels of microglial and 361 brain CH25H mRNA, we hypothesize that 25-HC may be an important proinflammatory 362 chemical messenger whose production and secretion will greatly amplify cytokine 363 secretion in apoE4-expressing microglia in a paracrine or autocrine manner, and may 364 thus contribute either indirectly or even directly to the neuroinflammation and 365 neurodegeneration that characterize AD. In this regard, Jang and colleagues (66) have 366 recently shown that 25-HC has proinflammatory actions in a study of X-linked 367 adrenoleukodystrophy (X-ALD), a progressive neurodegenerative disorder characterized 368 by accumulation of very long-chain fatty acids (VLCFA). They observed that 25-HC is 369 markedly increased in X-ALD brain tissue, promotes IL-1b production and 370 neuroinflammation and is directly neurotoxic when administrated to brain in vivo (66). However, we did not observe any change of pro-IL-1b mRNA or protein levels in 25-HC 376 treated microglia, suggesting that 25-HC augments cytokine production via a 377 posttranslational mechanism. The induction of IL-1b production is dependent on two 378 signals: first, activation of TLR4 on the cell surface by stimuli such as LPS leading to IL-379 1b mRNA generation and pro-IL-1b production. A second process derives from 380 inflammasome activation by stimuli such as ATP which leads to recruitment and activation 381 of caspase-1, a protease that cleaves pro-IL-1b into mature IL-1b. We found that 25-HC 382 efficiently promotes IL-1b production in the presence of LPS, however, 25-HC does not 383 activate IL-1b production by itself at either the mRNA or protein level. These observations 384 suggest that 25-HC might directly or perhaps indirectly activate caspase-1 inflammasome 385 activity in microglia. In fact, we observed markedly reduced IL-1b production when 25-HC 386 and LPS were coincubated in the presence of the caspase-1 inhibitor VX765 or when K+ P301S tau transgenic mice that are homozygous for human APOE2 (TE2), APOE3 436 (TE3), APOE4 (TE4) or with no expression of apoE (TEKO) (C57BL/6) were generated 437 by the Holtzman laboratory at Washington University, St. Louis as described previously 438 (37). TLR4 knockout mice were purchased from the Jackson laboratory (JAX stock 439 #029051) and maintained as homozygotes. All animals were maintained in a pathogen-440 free environment, and experiments on mice were conducted according to the protocol 441 approved by the Weill Cornell Medicine Animal Care Committee. to be microglia (Iba-1 positive) by immunohistochemistry. After seeding for 24 hrs, cells 458 were washed once with serum-free medium and treated with various reagents in serum-459 free DMEM/F12 medium supplemented with 0.02% BSA. The reagents used in 460 microglia treatment were: LPS (Sigma, L5293, Escherichia coli, 0111:B4); ATP (sigma 461 A2383); 25-hydroxycholesterol (Avanti#700019 or Sigma H1015); cholesterol 462 (Avanti#700100); 7 a-hydroxycholesterol (Avanti#700034); VX-765 (Medchemexpress). 463
Ent-25-hydroxycholesterol was synthesized as described (77). Quantification of 25-hydroxycholesterol. Primary microglia were prepared and 504 treated as described above. Media was collected and frozen at -80°C after removing 505 floating cells. For each sample, 5 µL of methanol or 5 µL of deuterated internal standard 506 at a concentration of 500 ng/mL were added to 50 µL of microglia growth media 507 separately before being mixed and then hydrolyzed using 1N KOH at 90°C for two 508 hours. The samples were then liquid-liquid extracted with methyl tert-butyl ether and 509 the organic phase evaporated to dryness under air at 50°C. Sample residues were 510 reconstituted in 100 µL of 80% methanol. Reconstituted samples (5ul) were then 511 injected onto an Eksigent microLC 200 system. Separation was effected with a Waters 512 Acquity 1 mm x 50 mm C18 reverse-phase column at 50 µL/min over seven minutes. 513 Data were acquired by an ABSciex QTRAP 5500 mass spectrometer using the Turbo 514
Spray source maintained at 300°C. Spray voltage was maintained at 4000 volts, curtain 515 gas at 40 L/min, gas 1 at 30 L/min, and gas 2 at 30 L/min. Chromatographic peak areas 516 of transition 385.4/367.4 (CE=25V, DP=60V) were integrated and quantified using 517 : LPS stimulates 25HC production and CH25H expression in primary microglia and in mouse brain. a) LPS stimulates 25-HC production and secretion in primary microglia in a time-and dose-dependent manner. Primary microglia were treated with LPS (0, 10 and 100ng/ml) for 6 and 24 hours. The levels of 25-HC in cells (a) and media (b) were determined by GC-MS. ****p<0.001 by ordinary one-way ANOVA. c) LPS induces the expression of CH25H, IL-1b, TNFa and NLRP3 inflammasome mRNA in primary microglia. The comparative gene expressions were determined by qPCR using RNA extracted from primary microglia with or without 10ng/ml LPS treatment for 24hrs. Insert: CH25H protein level in wt or CH25H-/-primary microglia treated with or without 10ng/ml LPS. It is a representative result of two independent experiments. d) Gene expression analysis of CH25H, IL-1b, TNFa, Cyp7b and Cyp27a1 in brain tissue of C57BL6 mice treated with 8.2mg/kg LPS (n=3) for 24 hours as determined by qPCR. * p<0.05,**p<0.01 ***p<0.005 by student t-test comparing LPS-treated mouse brain to saline treated control brain.
Figure 3: 25-HC selectively amplifies LPS-induced IL-1b expression and secretion. a-c)
WT and CH25H KO primary microglia were treated with LPS (0, 0.1, 1, 10, 100ng/ml) for 24hrs. The levels of secreted IL-1b (a), IL-1a (b) and TNFa (c) in the medium were measured by ELISA. d) The levels of secreted IL1b from WT and CH25H KO microglia treated with LPS (10ng/ml) with or without 25-HC (10µg/ml) were measured by ELISA. e) Primary microglia were treated with 10ng/ml LPS in the presence of different concentrations of 25-HC for 24 hours. The levels of IL-1b in the media were determined by ELISA and f) the levels of intracellular pro-IL1b and mature IL1b secreted in the media as measured by Western blotting. Statistical analyses were determined by multiple ttest in a, b, c, d; one-way ANOVA in e. * p<0.05, **p<0.01, ***p<0.005, ****p<0.001. The data shown are representative for three or more independent experiments. Figure 4: Exaggerated IL-1b and 25-HC production in LPS-activated microglia expressing human ApoE4. The levels of IL-1b or IL-6 secreted into the medium in apoE2or apoE4-expressing microglia or apoE KO microglia treated with LPS (10ng/ml) and 25-HC (0, 1, 2, or 10µg/ml) for 6 h (a) or 24 h (b and c). The levels of IL-1b secreted in the medium of apoE3-or apoE4-expressing microglia after 24 h treatment with LPS (10ng/ml) and 25-HC (10µg/ml) (d, e) and the levels of 25-HC in these cells or medium were determined by GC-MS (f). Statistical significances were determined by two-way ANOVA with multiple comparisons in a, b, c, d or unpaired student t-test in f. * p<0.05, **p<0.01, ***p<0.005, ****p<0.001, respectively. The data shown are representative for three or more independent experiments.
Figure 5: IL-1b/a induction by 25-HC is highly specific. The levels of secreted IL-1b (a), IL-1a (b) or IL-6 (c) in the medium of primary microglia treated with LPS (10ng/ml) in the presence of 25-HC (10µg/ml), Cholesterol (10µg/ml) or 7a-HC (10µg/ml) for 24 hrs. d) Ent-25-HC (10µg/ml) has much weaker effects in augmenting IL-1b production in primary microglia treated with LPS (10ng/ml) for 24hr. The levels of cytokines were determined by ELISA. Statistical significances were determined by ordinary two-way ANOVA with Tukey multiple comparisons test. * p<0.05, **p<0.01, ***p<0.005, ****p<0.001. The data shown are representative for two or more independent experiments. Figure 6: 25-HC induces inflammasome activation. ASC specks in microglia treated with LPS (10ng/ml) w/o or with 25-HC (10µg/ml) were stained by ASC antibody (green) and DAPI for Nuclei (blue) (a). Quantification of ASC specks in microglia treated with medium alone (ctl), medium containing LPS (10ng/ml), 25-HC (10µg/ml) or LPS (10ng/ml) plus 25-HC (10µg/ml ) (b). WT or TLR4 deficient microglia were treated with LPS (10ng/ml) and 25-HC (10µg/ml) for 24 h followed by ASC antibody staining (green) and DAPI (blue) (c) or ELISA measurements of secreted IL1b (d). Inhibition of caspase 1 by VX765 (e) or a high concentration of potassium (50mM) (f) in the medium prevents 25-HC-dependent IL-1b production in microglia treated with 10ng/ml LPS for 24 h. Statistical analyses were determined by ordinary two-way ANOVA with Tukey multiple comparisons test in c, e and f or student ttest in d. * p<0.05, **p<0.01, ***p<0.005, ****p<0.001. The data shown are representative for three or more independent experiments.
